Ray's MSD and Novo Holdings-backed Series B will shed light on the potential of the company's vision restoration gene therapy pipeline.
The treatment landscape for locally advanced head and neck squamous cell carcinoma (LA HNSCC) has changed significantly.
The US Government will now pick up the cost of weight loss drugs offered through the Medicare GLP-1 Bridge scheme until 31 December 2027.
Idvynso is the first non-INSTI, tenofovir-free, two-drug regimen to get the FDA’s blessing. Credit: Tatyana Frolova / Shutterstock.com. MSD (Merck & Co) has secured a US approval for its two-drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results